Breaking News and Updates
- Abolition Of Work
- Alternative Medicine
- Artificial Intelligence
- Atlas Shrugged
- Ayn Rand
- Basic Income Guarantee
- Big Tech
- Black Lives Matter
- Boca Chica Texas
- Casino Affiliate
- Cbd Oil
- Chess Engines
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Designer Babies
- Donald Trump
- Elon Musk
- Ethical Egoism
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom of Speech
- Gene Medicine
- Genetic Engineering
- Germ Warfare
- Golden Rule
- Government Oppression
- High Seas
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Longevity
- Immortality Medicine
- Intentional Communities
- Jordan Peterson
- Life Extension
- Marie Byrd Land
- Mars Colonization
- Mars Colony
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- National Vanguard
- New Utopia
- Online Casino
- Personal Empowerment
- Political Correctness
- Politically Incorrect
- Post Human
- Post Humanism
- Private Islands
- Quantum Computing
- Quantum Physics
- Resource Based Economy
- Ron Paul
- Second Amendment
- Second Amendment
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Teilhard De Charden
- The Singularity
- Tor Browser
- Transhuman News
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Zeitgeist Movement
The Evolutionary Perspective
Category Archives: Psoriasis
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities – DocWire News
Posted: April 18, 2020 at 3:44 am
Plaquepsoriasiscan occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion demonstrated efficacy and safety in patients with moderate-to-severe localized plaquepsoriasis. This analysis evaluated patients where a psoriatic target lesion was identified on the leg.
In two phase 3, multicenter, double-blind studies, participants were randomized (2:1) to receive HP/TAZ or vehicle lotion once-daily for 8 weeks. This pooled, post hoc analysis included a subset of participants who had a leg target lesion (HP/TAZ, n=148; vehicle, n=71). Efficacy assessments included treatment success (2-grade improvement) inpsoriasissigns (erythema, plaque elevation, scaling) on the leg target lesion, and overall treatment outcomes, including overall treatment success (2-grade improvement in Investigators Global Assessment [IGA] score and score of clear/almost clear), affected Body Surface Area (BSA), and IGAxBSA composite score.
Psoriasissigns were reduced by week 8, with more HP/TAZ treated participants achieving treatment success for erythema (41.6%), plaque elevation (58.5%), and scaling (59.5%) on the leg compared with vehicle (12.5%, 19.2%, and 21.0%, respectively; P<0.001 all). Significantly more participants achieved overall treatment success at week 8 with HP/TAZ versus vehicle (36.4% vs 10.4%; P<0.001). The HP/TAZ group also had a greater mean reduction in affected BSA and IGAxBSA score versus vehicle (P<0.001, both). The most frequently reported treatment-related adverse event (incidence, 3%) with HP/TAZ was contact dermatitis.
HP 0.01%/TAZ 0.045% lotion was associated with significant reductions in disease severity and good tolerability following 8 weeks of treatment in patients where a psoriatic target lesion was identified on the leg. J Drugs Dermatol. 2020;19(4):389-396. doi:10.36849/JDD.2020.4958.
Determinants of sleep impairment in psoriatic arthritis: an observational study with 396 patients from 14 countries – DocWire News
Posted: at 3:44 am
Sleep quality is diminished in patients with psoriaticarthritis(PsA) and close to 40% of PsA patients consider sleep difficulties a priority domain. This work analyzes determinants of impaired sleep in patients with PsA.
This was a cross-sectional analysis of an observational study (ReFlap, NCTNCT03119805), which included adult patients with definite PsA with 2 years disease duration from 14 countries. Sleep was assessed using the patient self-reported evaluation of sleep on a 0-10 numerical scale, included in the PsoriaticArthritisImpact of Disease questionnaire (PSAID-12). A score 4 was considered as sleep impairment. Demographic and clinical variables associated to sleep impairment were assessed through univariate analysis and Poisson regression modeling leading to prevalence ratio (PR) [95% confidence interval].
A total of 396 patients were analyzed: mean age 51.912.6 years, 51% were females, 59.7% were receiving biologic therapy, 53.3% had 1-5% of body surface area affected by psoriasis; 23.7% were in remission and 36.9% in low disease activity according to the Disease Activity in PsoriaticArthritis(DAPSA) score. Median (25th-75th) patients self-evaluation of sleep difficulties was 2 (0-6), 157 (39.6%) had sleep impairment. In the Poisson regression model, self-reported levels of anxiety (PR: 1.05 [1.02-1.08], p=0.003) and pain (PR: 1.06 [1.04-1.09], p<0.001) were independently associated to sleep impairment.
In this multicentric study, sleep impairment was present in 40% of PsA patients; pain and anxiety were associated to sleep impairment whereas inflammation was not. Impact on sleep appears multifactorial in PsA.
Posted: April 1, 2020 at 3:41 am
Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty payments in the mid- to high-single digits.
Sitryx grants Lilly exclusive, worldwide license to develop and commercialize up to four immunometabolism targeted compounds, including Sitryxs two lead projects. The partnership will run for five years, with Sitryx taking on drug discovery and Lilly paying for and handling clinical development and commercialization.
As Lilly seeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners, said Ajay Nirula, vice president of immunology at Lilly. Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets.
Sitryx was founded in 2018 with seed funding from SV Health Investors and by six researchers in immunology and immuno-regulation: Houman Ashrafian (SV Health Investors), Luke ONeill (Trinity College Dublin), Jonathan Powell (Johns Hopkins), Jeff Rathmell (Vanderbilt University), Michael Rosenblum (University of California San Francisco) and Paul Peter Tak (formerly chief immunology officer, global development leader and senior vice president R&D Pipeline at GlaxoSmithKline; Amsterdam University Medical Centre). It raised $30 million in Series A funding from SV Health Investors, Sofinnova Partners, Longwood Fund and GlaxoSmithKline in 2018.
The scientific focus of the company is regulating cell metabolism to treat diseases.
We are excited to partner with Lilly, one of the global leaders in the field of immunology, to pursue the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory diseases in the fast-emerging area of immunometabolism, said Neil Weir, chief executive officer of Sitryx. This agreement is transformational for Sitryx and further validates the strength of our scientific expertise and that of our Founder network and the potential for Sitryx to become a leader in this field.
Yesterday, Lilly announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) for the treatment of children ages six to 18 with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The application was based on a Phase III trial of 171 patients with moderate to severe plaque psoriasis. The trial had co-primary endpoints, including the proportion of patients hitting a 75% improvement on their Psoriasis Area and Severity Index Score (PASI 75) and a static Physicians Global Assessment of clear or almost clear skin at Week 12.
Due to limited pediatric psoriasis treatment options available, treating children and adolescents with moderate to severe plaque psoriasis can be challenging, said Stacie Bell, chief scientific and medical officer, National Psoriasis Foundation. Having more FDA approved pediatric psoriasis treatment options available is a positive step forward in helping relieve the burden of psoriasis for pediatric patients, their families and the health care providers that treat these young patients.
Read the original here:
Lilly and Sitryx Sign $880 Million+ 5-Year Development Deal - BioSpace
MicroRNA Signature May Predict Diagnosis and Treatment Response in Patients with PsA – Rheumatology Advisor
Posted: at 3:41 am
Compared with control participants, patients with psoriatic arthritis (PsA) display a significantly greater expression of 6 serum microRNAs (miRNAs), according to study results published in Journal of Rheumatology.1 In addition, baseline expression of certain serum miRNAs was associated with treatment response in patients with PsA.
Prior research has suggested that miRNA, small, noncoding RNA molecules, may serve as regulators in the pathogenesis of autoimmune diseases.2 The researchers sought to explore the relationship between serum miRNA levels and PsA.
Patients with PsA (n=31) were enrolled from outpatient rheumatology clinics at St Vincents University Hospital in Dublin, Ireland. All patients underwent baseline clinical and laboratory assessments, including quantification of C-reactive protein (CRP) levels and erythrocyte sedimentation rates (ESR). Follow-up visits were conducted at 3, 6, and 9 months after PsA treatment initiation. Patients were classified as either treatment responders or nonresponders according to the European League Against Rheumatism criteria. A cohort of healthy control participants (n=20) was enrolled from the community. All study participants underwent a peripheral blood draw; a focused immunology panel of 68 miRNAs of interest was analyzed for each serum sample. The miRNA that were differentially expressed between the 2 study groups were selected for further analysis. Area under the receiver operating characteristic curve (ROC) was used to assess the predictive capacity of each miRNA.
Of the identified miRNAs, 6 were significantly overexpressed in patients with PsA compared with control participants; the 6 miRNAs included miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p (all P <.001), and miR-21-5p (P <.01). According to ROC analyses, miR-130a-3p and miR-26a-5p emerged as the strongest predictors of PsA vs healthy control participants, with area under the curve values of 0.866 and 0.894, respectively. When miRNA expression was compared with nonspecific markers of inflammation, including ESR and CRP, only miR-130a-3p (r=0.53; P =.004) and miR-146a-5p (r=0.41; P =.03) correlated with CRP.
In addition, no significant associations were observed between miRNAs and ESR, suggesting that the 6-miRNA signature was PsA-specific and not just a marker of inflammatory disease. In prospective analyses, greater baseline expression of miR-130a-3p (P <.01), miR-221-3p, miR-146a-5p, miR-151a-5p, and miR-26a-5p (all P <.05) was associated with PsA therapeutic response vs nonresponse. Expression profiles did not appear to differ between patients receiving biologic vs nonbiologic therapies. The ROC analysis identified miR-221-3p, miR-130-3p, and miR-146a-3p as the strongest predictors of therapeutic response, with AUC values of 0.747, 0.760, and 0.717 respectively.
The results describe a serum microRNA signature with high discriminative capacity between PsA and control participants, as well as moderate prognostic capacity for PsA treatment response. Further study of these biomarkers is necessary to elucidate the pathogenesis of PsA.
1. Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ. Serum microRNA signature as a diagnostic and therapeutic marker in patients in patients with psoriatic arthritis [published online March 1, 2020]. J Rheumatol. doi:10.3899/jrheum.190602
2. Pauley KM, Cha S, Chan EKL. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3-4):189-194.
Posted: March 31, 2020 at 6:00 am
The skin is the bodys largest organismit is its defense against the worldso it makes sense that the immune system is very active in the skin, Tina Bhutani, M.D., M.A.S., a dermatologist and codirector of the University of California San Francisco (UCSF) Psoriasis and Skin Treatment Center and of the UCSF Dermatology Clinical Research Unit, tells SELF. But, she adds, researchers arent sure why some people get psoriasis and others dont.
We know patients have a genetic predisposition, but in addition, theres something environmental that happens to trigger their psoriasis, Dr. Bhutani explains. In some, that might be an infection, in others that might be some kind of stressor, like a psychological or physical stress on the body.
Research has shown that psoriasis can contribute to or worsen various mental health conditions, including depression, anxiety, bipolar disorder, eating disorders, and more. If you have psoriasis, you might be intimately familiar with how this worksespecially right now, given that basically all of us are feeling mental strain in unprecedented ways thanks to the new coronavirus.
While its a bit of a chicken-and-egg situation, Dr. Bhutani says that mental health conditions like anxiety or depression may kickstart the onset of psoriasis or trigger and exacerbate flare-ups. Beyond that, There are studies showing that major stressful life events, such as a death in the family, can result in the new onset of psoriasis, Joel Gelfand, M.D., MSCE (Master of Science in Clinical Epidemiology), professor of dermatology and epidemiology and director of the Psoriasis and Phototherapy Treatment Center at the Perelman School of Medicine at the University of Pennsylvania, tells SELF.
On the other hand is the fact that having psoriasis may contribute to you developing a mental health condition (or make it worse). There are studies that show patients with psoriasis are more likely to develop issues such as anxiety and depression over time, Dr. Gelfand says.
Anyone who has worried about not fitting in with narrow definitions of beauty can understand how having a visible skin condition could take a toll on someones mental health. One can imagine how the physical [stigma] of psoriasisespecially when plaques affect exposed areas of the skincan affect mood and interpersonal interactions in a negative way, Evan Rieder, M.D., an assistant professor of dermatology at NYU Langone who is board-certified in both psychiatry and dermatology, tells SELF. These can happen both through how someone with psoriasis views [themselves], but also through the reactions of others to their skin.
Like many people with psoriasis, Jennifer Pellegrin, 36, knows all too well how the condition can impact a persons social life and mental health. She was diagnosed with psoriasis when she was 15 and with psoriatic arthritis at 25, followed by depression a year later and then anxiety. Psoriasis causes an exacerbation of my [mental health conditions], she tells SELF in an email. I go through days sometimes where I cancel all plans. I can be looking forward to going out, start to get ready, and boom: Anxiety hits. I feel hideous and wont leave the house.
In addition to the more obvious ways psoriasis and mental health can play off each other, experts have done a fair amount of research into the biological mechanisms that may connect psoriasis and various mental health conditions. A 2016 systematic review in the Journal of Clinical and Aesthetic Dermatology looked at 57 studies on the subject, noting that psychological stress and depression can boost the release of pro-inflammatory cytokines, which are molecules released as part of the immune response. The inflammation they cause seems capable of further exacerbating the symptoms of both psoriasis and conditions like depression. However, theres conflicting research on this; some of the literature hasnt found definitive associations between psoriasis and psychological issues like stress.
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar…
Posted: at 5:59 am
HONGKONG, March 31, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2019 annual results, showing that the Company maintained steady growth, with core products continuously leading the market and more products being included into drug reimbursement lists. The Company has also been on track to advancing R&D pipelines, and stepping up efforts to introduce innovative therapies for cancer and autoimmune diseases into global markets. In the future, 3SBio will further boost its advantages with a comprehensive platform that integrates R&D, manufacturing, commercializationand investment cooperation, while consolidating and improving its status as a leading biopharmaceutical company.
Realizing sound business performance; sales of TPIAO exceeding RMB 2 billion
In 2019, 3SBio's revenue rose by 16.0% year on year to approximately RMB 5.318 billion. Gross profit increased by 18.5% to approximately RMB 4.393 billion. Normalized net profit attributable to owners of the parent added by 19.4% to approximately RMB13.92 billion.
The Company's four core products, including TPIAO, Yisaipu, EPIAO and SEPO, remained market leaders in China. Sales of TPIAO, which is the world's only commercialized recombinant human thrombopoietin ("rhTPO"), for the treatment of thrombocytopenia, soared 39.1% to exceed RMB 2 billion, with its market share jumping to 73.2%. Yisaipu, a product to treat rheumatoid arthritis , ankylosing spondylitis and psoriasis, had a market share of 60.9%. Two recombinant human erythropoietin ("rhEPO") products, EPIAO and SEPO, maintained market-leading positions, with their market share improving to 41.6%. As there is huge unmet demand for biologics in China, TPIAO and Yisaipu, which have low penetration rates, will see significant growth potential in the future.
Several of the Company's products and indications have been added into the updated 2019 National Reimbursement Drug List (NRDL), including Shinuo, a fluticasone propionate cream for the treatment of multiple skin diseases, the new indication of Yisaipu for the treatment of adult patients with severe plaque psoriasis, and the new indication for EPIAO for the treatment of anemia caused by chemotherapy for non-myeloid malignant tumors. Humulin, a mixed protamine zinc recombinant human insulin injection, was upgraded to Class A from Class B in the NRDL. Byetta, a therapy for the treatment of patients with type 2 diabetes, was added into the NRDL through negotiations.
Also, Xenopax, the first approved recombinant humanized anti-CD25 monoclonal antibody injection in China, was granted the Chinese GMP certificate and launched in the market in October, 2019.
R&D expenses up 45.2%, with follow-up pipelines on 'fast track'
In 2019, 3SBio's R&D expenses soared by 45.2% to approximately RMB 527 million. The Company has its best-ever pipeline of biological cancer therapies, including anti-HER2, CD20, PD1, EGFR and VEGF antibodies. The Company's pipeline of biological therapies for the treatment of autoimmune and inflammatory diseases, including anti-TNFa, IL-17A and IL-5 antibodies, has all made significant progress.
302H (Inetetamab), an anti-HER2 monoclonal antibody drug, has completed the technical review, clinical trial site inspection as well as manufacturing site inspection. An application for manufacturing approval of pre-filled aqueous injection solution of Yisaipu has been filed and accepted by the National Medical Products Administration, and it is currently under the review process.
In 2019, the Company's drug candidates received five IND approvals, including: anti-PD1 antibody for the treatment of various cancers (simultaneous applications in China and the US); anti-IL-17A antibody for the treatment of moderate to severe plaque psoriasis; TRK820 (Remitch) for the treatment of pruritus in hemodialysis patients; and HIF-117 capsules for the treatment of anemia. In February 2020, the Company's anti-IL-5 antibody for the treatment of asthma was approved for a clinical trial.
The Company has also been proactively expanding new indications and second-generation products of existing products, including NuPIAO, a second-generation rhEPO; RD001, a pegylated long-acting rhEPO; and the pediatric ITP indication of TPIAO.
Also, the Company selected Verseau Therapeutics Inc's VTX-0811, a monoclonal antibody targeting PSGL-1 for the treatment of multiple types of cancer, as the first licensed program under the partnership in the field of immuno-oncology.
3SBio's R&D highlights in 2019
3SBios R&D highlights in 2019
As of December 31, 2019, amongst the 32 product candidates within the Company's active pipeline, 22 were being developed as National New Drugs in China (including registration Class I and Biologics Class II), including 11 in oncology, 12 in autoimmune and other diseases, 6 in nephrology, 2 in metabolic diseases and 1 in dermatology.
Expanding global presence in therapies for cancer and autoimmune diseases
In 2019, 3SBio was continuously expanding external partnerships and global presence for its innovative therapies in the fields of cancer and autoimmune diseases, including the partnership with global biologics giant Samsung Bioepis in South Korea for the development of biosimilar candidates; collaboration with Verseau Therapeutics in the United States for global clinical development of macrophage checkpoint modulators; partnership with Taiwan Liposome Company for the development of innovative liposomal products; and collaboration with Numab to develop new multispecific antibodies for cancer immunotherapy. The Company also invested GenSight and Sensorion to explore innovative gene therapies for ophthalmic diseases and innovative treatments for inner ear diseases.
In early 2020, the Company became a limited partner in the MPM Oncology Innovations Fund (INV), and agreed to make donation to support early-stage oncology research at Dana-Farber Cancer Institute, a world-leading cancer research and treatment center.
These collaborations demonstrated 3SBio's excellent expertise in international development and operation, while laying a key stepping stone for its future globalization strategy. The Company will continue to pursue selective mergers and acquisitions and collaboration opportunities and explore cutting-edge innovative therapies in early stages, with an aim to enrich its existing product portfolio and become a leader in next-generation immuno-oncology therapies.
Comprehensive platform with strong competitive advantages
In the future, 3SBio intends to reinforce its position as a leading biopharmaceutical company in China by continuously leveraging its integrated R&D, manufacturing, commercializationand investment cooperation platforms. The Company will also focus on developing innovative biologics products to address unmet medical needs to benefit more patients.
The Company will fully integrate the R&D teams of nearly 400 people on multiple R&D platforms, and actively develop innovative therapies including monoclonal antibodies, bispecific antibodies, antibody fusion proteins, and cell therapies, thereby bringing a variety of treatment options to patients. The Company will kick off multiple phase III clinical trials this year, file new drug applications for more than 10 products in the next 3 years, and also submit IND applications for10-15 new monoclonal antibodies and bispecific antibodies (simultaneous applications in China and the US).
The Company has approximately 38,000-liter capacity in mAb facility, mammalian cell-based, bacteria cell-based and small molecule manufacturing facilities, and more than 27 years of experience in manufacturing biologics medicines. With large-scale production capacity that meets international quality standards, the Company is able to continuously supply the market with high-quality biologics. Over nearly 3 decades, the Company has been well recognized for its strong commercial operation capabilities and sales network throughout the country, which supports its sustainable growth.
Dr. Jing LOU, Chairman and CEO of 3SBio, commented: "Under the backdrop of the COVID-19 pandemic globally, 3SBio supports the country in our own way, through thick and thin. As we face a market environment where opportunities and challenges coexist, 3SBio is still maintaining strong growth momentum by leveraging our well-established systems that we've developed over the years. we will strive to overcome all difficulties, accelerate clinical applications and progress for our pipeline. We will also expand our production capacity and give full play to the advantages of our integrated platform. We aim to become a globally leading Chinese biopharmaceutical company, and continuously improve the availability of innovative biologics to benefit more patients."
View original content to download multimedia:http://www.prnewswire.com/news-releases/3sbio-unveils-2019-annual-results-revenue-rises-by-16-0-normalized-net-profit-attributable-to-owners-of-the-parent-jumps-by19-4-rd-expenses-soar-45-2-301032239.html
SOURCE 3SBio Inc.
Global Psoriasis Treatment Market Industry Analysis and forecast (2019 to 2026) – Stock Market Herald
Posted: at 5:59 am
Global Psoriasis Treatment Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 9.3 % during forecast period of 2019 to 2026.
Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin growth, skin patches are typically red, dry, itchy, and scaly.
Global Psoriasis Treatment Market Drivers and Restrain
Rising prevalence of the condition, heading with growing awareness, the screening and diagnosis of the disease are expected to fuel the global psoriasis treatment market in the coming years. Psoriasis treatment options also contribute to a number of side-effects such as liver and kidney damage, hypertension, and increased risk of cancer, etc., are the factors could hamper the growth of Global Psoriasis Treatment Market in forecast period.
REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/37175
Global Psoriasis Treatment Market key segmentation
By drug class, the global market has been categorized into TNF inhibitors, Interleukin inhibitors, Vitamin D analogs, Corticosteroids, and others. Tumour Necrosis Factor Inhibitors is further categorized as Adalimumab, Infliximab, Etanercept. Vitamin D Analogues is segmented into Calcitriol, Calcipotriol, Tacalcitol. The Interleukin inhibitors segment is projected to lead the global psoriasis treatment market during the forecast period.
High market share of the interleukin inhibitors segment can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Moreover, the acceptance of this drug class is attributable to interleukin blockers, which are considered to be a viable option for patients having trouble responding to other treatment.
Global Psoriasis Treatment Market Regional Analysis
By region, the global psoriasis market to witness dominance of North America followed by Europe. As per the National Psoriasis Foundation, there are about X million people in America living with psoriasis. Because of quick adoption of biological therapy and rise in investments on research and development for clinical trials will drive global market in this region. On the other side, the emerging markets in the Middle East and Africa, Latin America, and Asia Pacific are expected to offer growth opportunities thanks to increasing patient pool, the improving healthcare infrastructure and medical facilities.
The objective of the report is to present comprehensive analysis of Global Psoriasis Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding Global Psoriasis Treatment Market dynamics, structure by analyzing the market segments, and project the Global Psoriasis Treatment Market size. Clear representation of competitive analysis of key players by Psoriasis Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Psoriasis Treatment Market.
DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/37175
Scope of the Global Psoriasis Treatment Market
Global Psoriasis Treatment Market Drug class
Corticosteroids Tumour Necrosis Factor Inhibitors interleukin inhibitors Vitamin D AnaloguesGlobal Psoriasis Treatment Market by Treatment
Biologic Drugs Small Molecule Systemic Drugs Tropical TherapiesGlobal Psoriasis Treatment Market by Route of administration
Oral Parenteral TopicalGlobal Psoriasis Treatment Market by region
North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating on Global Psoriasis Treatment Market
AbbVie Inc., Amgen Inc., AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Stiefel Laboratories Inc. (GlaxoSmithKline plc.), Sun Pharmaceutical Industries
MAJOR TOC OF THE REPORT
Chapter One: Psoriasis Treatment Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Psoriasis Treatment Market Competition, by Players
Chapter Four: Global Psoriasis Treatment Market Size by Regions
Chapter Five: North America Psoriasis Treatment Revenue by Countries
Chapter Six: Europe Psoriasis Treatment Revenue by Countries
Chapter Seven: Asia-Pacific Psoriasis Treatment Revenue by Countries
Chapter Eight: South America Psoriasis Treatment Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Psoriasis Treatment by Countries
Chapter Ten: Global Psoriasis Treatment Market Segment by Type
Chapter Eleven: Global Psoriasis Treatment Market Segment by Application
Chapter Twelve: Global Psoriasis Treatment Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Psoriasis Treatment Market Report at: https://www.maximizemarketresearch.com/market-report/global-psoriasis-treatment-market/37175/
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Vikas Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Contact: +919607065656/ +919607195908
Posted: March 24, 2020 at 4:58 am
Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.
Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.
Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.
Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.
Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.
Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.
Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.
Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.
National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.
Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.
Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).
Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.
Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.
See the original post:
Psoriasis: Types, Pictures, Causes, Symptoms, Treatments ...
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market – Daily Local News
Posted: at 4:58 am
EXTON, Pa., March 17, 2020 /PRNewswire/ --The past decade has ushered in an array of new treatment options for moderate-to-severe plaque psoriasis, providing dermatologists with more than they bargained for and often times making it difficult to compare efficacy across medications. Thus, it has become crucial for companies to differentiate their assets both within and outside their drug class whether it be through head-to-head clinical trials, patient assistance programs, or building a dermatology portfolio to establish trust and a relationship as a respected partner in the field.
A noteworthy example of a company differentiating themselves from the pack is AbbVie, particularly with the launch of their third-in-class IL-23 inhibitor, Skyrizi, in psoriasis. According to the latest quarterly report included in Spherix's RealTime Dynamix: Plaque Psoriasis (US) service, brand share for fellow IL-23 inhibitor, Janssen's Tremfya, as well as the IL-17 inhibitors, Novartis' Cosentyx and Eli Lilly's Taltz, have remained relatively flat, while AbbVie's newest market entrant has experienced exponential growth since its April 2019 introduction. Impressively, nearly two-thirds of the 101 US dermatologists surveyed selected Skyrizi as their most preferred IL-23 inhibitor if limited to just one for the treatment of psoriasis, despite Tremfya's almost three-year tenure on the market.
Skyrizi's early success in psoriasis is likely attributed to a multitude of factors. Dermatologists report frequent contact with Skyrizi representatives, elevated satisfaction with the Skyrizi Complete program, high awareness of AbbVie's head-to-head post-marketing study demonstrating superiority over Cosentyx on skin clearance, and overall greater perceived efficacy compared to other alternate mechanism of action agents. Furthermore, the manufacturer is beginning to build onto their already well-received Humira legacy, expanding their dermatology portfolio an approach many big players in the field are partaking in.
AbbVie, Amgen, Eli Lilly, Janssen, and Novartis all own commercial products for the treatment of psoriasis as well as pipeline assets in atopic dermatitis (AD), with Pfizer holding pipeline assets in both indications. With only one biologic (Regeneron/Sanofi's Dupixent) currently FDA approved for the treatment of moderate to severe AD and a myriad of companies (aside from those listed above) with agents in the pipeline, the future advanced systemic market in AD has the potential to mirror the current psoriasis biologic landscape.
According to the Q1 2020 report included in Spherix's RealTime Dynamix: Atopic Dermatitis (US)service, 85% of surveyed dermatologists foresee the AD market emulating that of the crowded psoriasis market. Respondents also report a biologic/small molecule patient candidacy pool that is substantially larger than those currently treated with Dupixent and one that is comparable to the biologic-treated patient load in psoriasis.
Despite anticipated resemblances between the two markets, AD patients will likely be treated with more small molecule options, specifically JAK inhibitors. With the oral JAK inhibitors' (Lilly's Olumiant/baricitinib, Pfizer's abrocitinib, and AbbVie's Rinvoq/upadacitinib) projected launches around the corner, their location in the AD treatment paradigm will be key to uptake. Currently, one-half of dermatologists report it is unlikely these agents will be used prior to biologics in AD, which is how many prefer to utilize BMS' Otezla for the treatment of moderate to severe psoriasis. Instead, dermatologists will likely follow in the footsteps of rheumatologists, where both Pfizer's Xeljanz and AbbVie's Rinvoq currently play in-line with the injectable biologics in RA.
Dermatologists also await the approval of topical JAK inhibitors for the treatment of AD (specifically Incyte's topical ruxolitinib and LEO's topical delgocitinib) and anticipate using these agents prior to oral JAK inhibitor use, in less severe patients, and for short-term flare management.
With a plethora of pipeline agents with the same mechanism of action and comparable efficacy, it comes down to the strategies these manufacturers are implementing across dermatology to build trust with prescribers around their brands, hence the creation of a dermatology portfolio. Spherix will be closely tracking products in development as well as newly launched brands in both markets through the RealTime Dynamixservices.
About RealTime DynamixRealTime Dynamix: Plaque Psoriasis (US) is an independent service providing strategic guidance through rapid and comprehensive quarterly reports, which include psoriasis market trending, launch tracking, and a fresh infusion of unique content with each wave.
A parallel service, RealTime Dynamix: Atopic Dermatitis (US), tracks the evolution of the US atopic dermatitis market on a quarterly basis.
About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:Lynn Price, Immunology Franchise HeadEmail:email@example.com
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices -…
Posted: at 4:58 am
The aim of this study was to evaluate the discriminant capability of the Patient Acceptable Symptom State (PASS) according to disease activity, remission/low disease activity indices and quality of life indices in patients withpsoriatic arthritis(PsA).
Consecutive patients with PsA were enrolled in this cross-sectional study. At each visit, the patients underwent a complete physical examination and their clinical/laboratory data were collected. Disease activity was assessed using the Disease Activity Score forPsoriatic Arthritis(DAPSA) and remission/low disease activity using the DAPSA minimal disease activity (MDA) and very low disease activity (VLDA) criteria. ThePsoriatic ArthritisImpact of Disease (PsAID) and the Health Assessment Questionnaire-Disability Index scores were also collected. Finally, PASS was assessed by asking all patients to answer yes or no to a single question.
Patients who answered yes to PASS showed a significantly better overall mean DAPSA score than those who were not in PASS. Furthermore, patients in PASS showed a significantly lower level of systemic inflammation, lower Leeds Enthesitis Index score, a significantly lower impact of disease (PsAID), lower pain and better function than patients who answered no to PASS. A moderate to good agreement was found between PASS, MDA, DAPSA low disease activity and PsAID score 4. Good sensitivity and specificity were found with PASS with respect to DAPSA low disease activity, and although PASS is sensitive in the identification of patients with MDA, DAPSA remission and VLDA it lacks of specificity.
This study showed that PASS might be used as an alternative to determine disease activity in patients with PsA in real clinical practice, mainly in patients with low disease activity according to DAPSA criteria.